Aquestive Therapeutics, Inc. Accrued Marketing Costs, Current
Aquestive Therapeutics, Inc. (AQST) had Accrued Marketing Costs, Current of $906.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedMarketingCostsCurrent · last filed 2026-03-04
- 2025-12-31: Accrued Marketing Costs, Current $906.00K.
- 2024-12-31: Accrued Marketing Costs, Current $665.00K.
- 2024-09-30: Accrued Marketing Costs, Current $665.00K.
- 2023-12-31: Accrued Marketing Costs, Current $645.00K.
| Period end | Accrued Marketing Costs, Current |
|---|---|
| 2025-12-31 | $906.00K 10-K · filed 2026-03-04 |
| 2024-12-31 | $665.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $665.00K 10-K · filed 2025-03-05 |
| 2023-12-31 | $645.00K 10-K · filed 2025-03-05 |
| 2022-12-31 | $1.01M 10-K · filed 2024-03-05 |
| 2021-12-31 | $2.22M 10-K · filed 2023-03-31 |
| 2021-03-31 | $1.81M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $1.72M 10-K · filed 2022-03-08 |
| 2020-09-30 | $1.66M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $1.40M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $1.41M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $1.17M 10-K · filed 2021-03-09 |
| 2019-09-30 | $1.06M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $809.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $641.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $481.00K 10-K · filed 2020-03-11 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |